Boston, MA (July 5, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with...
Oncology Venture A/S (“OV” or the Company) today announced an update on the progress of its planned Phase 2 clinical trial for IXEMPRA® (Ixabepilone) for the treatment of breast cancer.
The U.S. FDA compiles a list of off-patent drugs without an approved generic to encourage the development of copycats. Now, the Chinese authorities are rolling out a similar initiative, only with some extra incentives.